跳至主要内容
临床试验/NCT01655862
NCT01655862已完成不适用

Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Cervical Dystonia and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (POSTURe)

Allergan8 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2012年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
62
试验地点
8
主要终点
Change from Baseline in Cervical Dystonia Impact Profile Questionnaire (CDIP-58) Score

研究概览

简要总结

This is an observational study to assess health-related quality of life in patients with cervical dystonia (dystonie) treated with OnabotulinumtoxinA per routine clinical practice.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of cervical dystonia (dystonie) and able to receive botulinum toxin Type A as deemed medically necessary by the physician

排除标准

  • Participation in a clinical trial for any botulinum toxin indication
  • Planning elective surgery during the observational study period
  • Treatment with any botulinum toxin product for cervical dystonia (dystonie)
  • Treatment with any botulinum toxin product for a non-cervical dystonia (dystonie) condition within 2 months of study start

结局指标

主要结局

Change from Baseline in Cervical Dystonia Impact Profile Questionnaire (CDIP-58) Score

时间窗: Baseline, 96 Weeks

次要结局

  • Change from Baseline in Hospital Anxiety and Depression Scale (HAD) Score(Baseline, 96 Weeks)
  • Work Productivity Assessment Using a 10-Item Questionnaire(96 Weeks)
  • Patient's Global Impression of Change (PGIC) Using a 7-Point Scale(Baseline, 96 Weeks)
  • Reasons for Withdrawal of Treatment(96 Weeks)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验